Adagio Medical CFO granted 490,500 stock options

Adagio Medical Holdings, Inc. reported that Chief Financial Officer Deborah Kaster acquired 490,500 employee stock options on March 6, 2026.

Rhea-AI Filing Summary

Adagio Medical Holdings, Inc. reported that Chief Financial Officer Deborah Kaster acquired 490,500 employee stock options on March 6, 2026. These options were granted under the company’s 2024 Equity Incentive Plan as a compensation award, not an open‑market share purchase.

According to the vesting terms, 25% of the option grant will vest on October 20, 2026, and the remaining options will vest in 36 equal monthly installments after that date. Following this grant, she holds 490,500 derivative securities directly.

Insider Trade Summary

Grant/Award: 490,500 shares

Grant/Award 1 txn

Insider Kaster Deborah

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Employee Stock Options (Right to Buy)	490,500	$0.00	$0.00

Holdings After Transaction: Employee Stock Options (Right to Buy) — 490,500 contracts for 490,500 underlying shares (Direct)

Footnotes (1)

1. F1. Employee Stock Options granted pursuant to Issuer's 2024 Equity Incentive Plan (the "Option"). The Option will vest over a four-year period, whereby twenty-five percent (25%) of the Option will vest on October 20, 2026, with the remaining shares subject to the Option vesting in thirty-six (36) equal monthly installments thereafter.

FAQ

What insider transaction did Adagio Medical (ADGM) disclose in this Form 4?

Adagio Medical disclosed a grant of 490,500 employee stock options to Chief Financial Officer Deborah Kaster. The award is a derivative security grant under the 2024 Equity Incentive Plan, rather than an open‑market purchase or sale of common stock.

Who is the reporting person in Adagio Medical (ADGM)’s latest Form 4?

The reporting person is Deborah Kaster, Chief Financial Officer of Adagio Medical Holdings, Inc. She reported receiving a grant of 490,500 employee stock options, held directly, as part of her compensation under the company’s 2024 Equity Incentive Plan.

How many Adagio Medical (ADGM) options were granted to the CFO?

The Chief Financial Officer received a grant of 490,500 employee stock options. This derivative award increases her directly held derivative securities to 490,500 following the transaction reported on March 6, 2026, according to the Form 4 disclosure data.

What is the vesting schedule for the Adagio Medical (ADGM) options granted?

The option grant vests over four years. 25% of the options vest on October 20, 2026, with the remaining shares vesting in 36 equal monthly installments thereafter, as specified in the Form 4 footnote for the 2024 Equity Incentive Plan award.

Is the Adagio Medical (ADGM) Form 4 transaction a purchase or a grant?

The Form 4 reports a grant/award acquisition of employee stock options, coded as transaction type “A.” It reflects compensation issued under the 2024 Equity Incentive Plan, not a cash purchase or sale of common shares on the open market.

Does the Adagio Medical (ADGM) Form 4 show direct or indirect ownership?

The filing shows the 490,500 employee stock options as held with direct ownership. No trust, partnership, or other indirect holding entity is referenced for this transaction, and there is no footnote disclaiming beneficial ownership or voting and investment power.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/09/2026 - 06:04 AM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kaster Deborah

(Last) (First) (Middle)

C/O ADAGIO MEDICAL HOLDINGS, INC.

26051 MERIT CIRCLE, SUITE 102

(Street)

LAGUNA HILLS CA 92653

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Adagio Medical Holdings, Inc. [ ADGM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/06/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Options (Right to Buy)	$0.977	03/06/2026		A		490,500		(1)	03/06/2036	Common Stock	490,500	$0	490,500	D

Explanation of Responses:

1. Employee Stock Options granted pursuant to Issuer's 2024 Equity Incentive Plan (the "Option"). The Option will vest over a four-year period, whereby twenty-five percent (25%) of the Option will vest on October 20, 2026, with the remaining shares subject to the Option vesting in thirty-six (36) equal monthly installments thereafter.

	/s/ Deborah Kaster	03/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.